Overview Dividends

(VTRS) Viatris - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92556V1061

Brand, Generic, Biosimilar, Complex, Dose

VTRS EPS (Earnings per Share)

EPS Growth (3Y CAGR): 0.00%
EPS Trend (3Y Correlation): -54.8%

VTRS Revenue

Revenue Growth (3Y CAGR): -1.10%
Revenue Trend (3Y Correlation): -60.7%

Risk via 10d forecast
Volatility	32.5%
Value at Risk 5%th	50.0%
Relative Tail Risk	-6.50%

Reward TTM
Sharpe Ratio	-0.35
Alpha	-25.01

Character TTM
Hurst Exponent	0.479
Beta	0.792
Beta Downside	1.053

Drawdowns 3y
Max DD	45.02%
Mean DD	16.32%
Median DD	16.53%

Description: VTRS Viatris October 31, 2025

Viatris Inc. (NASDAQ: VTRS) is a globally diversified healthcare company operating across North America, Europe, Greater China, Japan-Australia-New Zealand (JANZ), and emerging markets. Its business is organized into four geographic segments-Developed Markets, Greater China, JANZ, and Emerging Markets-and it markets a broad portfolio that includes prescription brands, generics, complex generics, and biosimilars covering therapeutic areas such as cardiovascular, CNS, diabetes, oncology, and respiratory diseases. Distribution channels span wholesale, retail, institutional, mail-order, e-commerce, and specialty pharmacies, and the firm also offers ancillary services like diagnostic clinics, educational programs, and digital health tools.

As of FY 2023, Viatris reported revenue of roughly $13.5 billion, with an adjusted EBITDA margin near 12%, reflecting the higher-margin mix from biosimilars and complex generics. The company’s growth is driven by three macro-level factors: (1) an aging global population increasing demand for chronic-disease therapies; (2) accelerating adoption of cost-effective biosimilars as payers tighten reimbursement policies; and (3) a projected 6% CAGR for the worldwide generic drug market through 2029, which benefits Viatris’s scale and diversified geographic footprint. Recent collaborations-such as the long-acting glatiramer acetate depot with Mapi Pharma and a Botox biosimilar with Revance-aim to expand its pipeline and capture additional market share in high-growth therapeutic niches.

If you want a data-rich, model-ready view of Viatris’s valuation dynamics, consider exploring the analytics on ValueRay for a deeper dive.

VTRS Stock Overview

Market Cap in USD	11,656m
Sub-Industry	Pharmaceuticals
IPO / Inception	2020-11-16
Return 12m vs S&P 500	-22.3%
Analyst Rating	3.44 of 5

VTRS Dividends

Dividend Yield	4.48%
Yield on Cost 5y	3.66%
Yield CAGR 5y	13.30%
Payout Consistency	57.4%
Payout Ratio	20.6%

VTRS Growth Ratios

CAGR 3y	3.81%
CAGR/Max DD Calmar Ratio	0.08
CAGR/Mean DD Pain Ratio	0.23
Current Volume	5964.9k
Average Volume	7561k

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (-3.69b TTM) > 0 and > 6% of Revenue (6% = 847.5m TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA -1.76pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 18.32% (prev 25.22%; Δ -6.90pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.03 (>3.0%) and CFO 1.24b > Net Income -3.69b (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 1.35 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (1.16b) change vs 12m ago -2.98% (target <= -2.0% for YES)

Gross Margin 36.07% (prev 39.90%; Δ -3.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 34.17% (prev 33.62%; Δ 0.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -7.16 (EBITDA TTM -598.9m / Interest Expense TTM 471.9m) >= 6 (WARN >= 3)

Altman Z'' -0.19

(A) 0.07 = (Total Current Assets 9.95b - Total Current Liabilities 7.36b) / Total Assets 37.92b

(B) -0.00 = Retained Earnings (Balance) -48.2m / Total Assets 37.92b

(D) -0.08 = Book Value of Equity -1.82b / Total Liabilities 22.70b

Total Rating: -0.19 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 29.12

1. Piotroski 3.50pt = -1.50

2. FCF Yield 3.54% = 1.77

3. FCF Margin 6.75% = 1.69

4. Debt/Equity 1.07 = 1.96

5. Debt/Ebitda -25.53 = -2.50

6. ROIC - WACC (= -15.15)% = -12.50

7. RoE -22.69% = -2.50

8. Rev. Trend -60.72% = -4.55

9. EPS Trend -54.78% = -2.74

What is the price of VTRS shares?

As of November 16, 2025, the stock is trading at USD 10.72 with a total of 5,964,924 shares traded.
Over the past week, the price has changed by +5.93%, over one month by +7.96%, over three months by +1.42% and over the past year by -10.96%.

Is Viatris a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Viatris (NASDAQ:VTRS) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 29.12 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VTRS is around 10.38 USD . This means that VTRS is currently overvalued and has a potential downside of -3.17%.

Is VTRS a buy, sell or hold?

Viatris has received a consensus analysts rating of 3.44. Therefor, it is recommend to hold VTRS.

Strong Buy: 2
Buy: 1
Hold: 5
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the VTRS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	12.1	13.2%
Analysts Target Price	12.1	13.2%
ValueRay Target Price	11.1	3.3%

VTRS Fundamental Data Overview November 11, 2025

Market Cap USD = 11.66b (11.66b USD * 1.0 USD.USD)
P/E Forward = 4.1425
P/S = 0.8252
P/B = 0.757
P/EG = 0.1436
Beta = 0.837
Revenue TTM = 14.12b USD
EBIT TTM = -3.38b USD
EBITDA TTM = -598.9m USD
Long Term Debt = 14.04b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.95b USD (from shortTermDebt, last quarter)
Debt = 16.26b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 15.29b USD (from netDebt column, last quarter)
Enterprise Value = 26.94b USD (11.66b + Debt 16.26b - CCE 975.3m)
Interest Coverage Ratio = -7.16 (Ebit TTM -3.38b / Interest Expense TTM 471.9m)
FCF Yield = 3.54% (FCF TTM 954.0m / Enterprise Value 26.94b)
FCF Margin = 6.75% (FCF TTM 954.0m / Revenue TTM 14.12b)
Net Margin = -26.13% (Net Income TTM -3.69b / Revenue TTM 14.12b)
Gross Margin = 36.07% ((Revenue TTM 14.12b - Cost of Revenue TTM 9.03b) / Revenue TTM)
Gross Margin QoQ = 36.83% (prev 37.21%)
Tobins Q-Ratio = 0.71 (Enterprise Value 26.94b / Total Assets 37.92b)
Interest Expense / Debt = 0.74% (Interest Expense 119.6m / Debt 16.26b)
Taxrate = -1523 % (out of range, set to none) (120.3m / -7.90m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.35 (Total Current Assets 9.95b / Total Current Liabilities 7.36b)
Debt / Equity = 1.07 (Debt 16.26b / totalStockholderEquity, last quarter 15.22b)
Debt / EBITDA = -25.53 (negative EBITDA) (Net Debt 15.29b / EBITDA -598.9m)
Debt / FCF = 16.02 (Net Debt 15.29b / FCF TTM 954.0m)
Total Stockholder Equity = 16.27b (last 4 quarters mean from totalStockholderEquity)
RoA = -9.73% (Net Income -3.69b / Total Assets 37.92b)
RoE = -22.69% (Net Income TTM -3.69b / Total Stockholder Equity 16.27b)
RoCE = -11.14% (EBIT -3.38b / Capital Employed (Equity 16.27b + L.T.Debt 14.04b))
RoIC = -11.41% (negative operating profit) (EBIT -3.38b / (Assets 37.92b - Curr.Liab 7.36b - Cash 975.3m))
WACC = 3.73% (E(11.66b)/V(27.92b) * Re(8.94%) + (debt cost/tax rate unavailable))
Discount Rate = 8.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.49%
[DCF Debug] Terminal Value 73.80% ; FCFE base≈1.34b ; Y1≈1.24b ; Y5≈1.13b
Fair Price DCF = 15.06 (DCF Value 17.35b / Shares Outstanding 1.15b; 5y FCF grow -9.15% → 3.0% )
EPS Correlation: -54.78 | EPS CAGR: 0.0% | SUE: 1.23 | # QB: 2
Revenue Correlation: -60.72 | Revenue CAGR: -1.10% | SUE: 2.32 | # QB: 2

Additional Sources for VTRS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle